Effects of norcantharridin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanics

National Medical Journal of China

Volumn 86, Issue 10, 2006, Pages 693-699

  Fan, Yue Zu ^a   Chen, Chun Qiu ^a   Zhao, Ze Ming ^a   Sun, Wei ^a  

^a TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Angiogenic inhibitors; Cantharidin; Gallbladder neoplasms; Neovascularization, pathologic

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; CYCLINE; ENDOSTATIN; FLUOROURACIL; MESSENGER RNA; NORCANTHARIDIN; SODIUM CHLORIDE; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; ANGIOSTATIN; ANTINEOPLASTIC ANTIMETABOLITE; FUSED HETEROCYCLIC RINGS; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FLOW CYTOMETRY; GALLBLADDER CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LD 50; MICROVASCULATURE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION; TUMOR VOLUME; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG EFFECT; DRUG SCREENING; GALLBLADDER TUMOR; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE; VASCULARIZATION;

ANGIOSTATINS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; FLUOROURACIL; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROLIFERATING CELL NUCLEAR ANTIGEN; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645473539     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Folkman J. Clinical applications of research on angiogenesis: seminars in medicine of the Beth Israel Hospital, Boston. N Engl J Med, 1995, 333:1757-1763.
2. Thompson WD, Li WW, Maragoudakis M. The clinical manipulation of angiogenesis: pathology, side effects, surprises, and opportunities with novel human therapies. J Pathol, 2000, 190:330-337.
3. Chinese source. 2005, 20:438-441.
4. Weinder N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat, 1995, 36:169-180.
5. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997, 88: 277-285.
6. Shi W, Teschendorf C, Muzyczka N, et al. Adeno-associated virus-mediated gene, transfor of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther, 2002, 9: 513-521.
7. Chinese source. 2002, 40:59-61.
8. Tanaka T, Konno H, Matsuda I, et al. Prevention of hepatic matastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res, 1995, 55:836-839.
9. Mendel DB, Laird AD, Smolich BD, et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des, 2000, 15:29-41.
10. Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res, 2000, 79:1-38.
11. Hotz HG, Hines OF, Hotz B, et al. Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. J Gastrointestinal Surg, 2003, 7:220-228.
12. Yamamoto S, Fujii K, Kitadai Y, et al. Expression of vascular endothelial growth factor in human gallbladder lesions. Oncol Rep, 1998, 5:1065-1069.
13. Norrby K. 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis. Int J Exp Pathol, 2000, 81: 191-198.
14. Stoeltzing O, Ahmad SA, McCarty MF, et al. Angiopoietin-1 inhibits tumor growth and ascites formation in a murine model of peritoneal carcinomatosis. Br J Cancer, 2002, 87:1182-1187.
15. Currie MJ, Gunningham SP, Turner K, et al. Expression of the angiopoietins and their receptor Tie 2 in human renal clear carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol, 2002, 198:502-510.
16. Gutierrez LS, Suckow M, Lawler J, et al. Thrombospondin-1: a regulator of adenoma growth and carcinoma progression in the APC (Min/+) mouse model. Carcinogenesis, 2003, 24:199-207.
17. Miyanaga K, Kato Y, Nakamura T, et al. Expression and role of thrombospondin-1 in colorectal cancer. Anticancer Res, 2002, 22: 3941-3948.
18. Hajitou A, Sounni NE, Devy L, et al. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2 effect on in vivo mammary tumor growth and angiogenesis. Cancer Res, 2001, 61: 3450-3457.